Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants

BackgroundAntibody–drug conjugates (ADC), such as enfortumab vedotin (EV), sacituzumab govitecan (SG), and RC-48, have shown outstanding response rates to local advanced or metastatic urothelial carcinoma (UC). However, their corresponding target expression characteristics in UC and its histologic v...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Yu Fan, Qinhan Li, Qi Shen, Zhifu Liu, Zhenan Zhang, Shuai Hu, Wei Yu, Zhisong He, Qun He, Qian Zhang
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2022-04-01
Sarja:	Frontiers in Oncology
Aiheet:	urothelial carcinoma ADC nectin-4 Trop-2 HER2 histologic variants
Linkit:	https://www.frontiersin.org/articles/10.3389/fonc.2022.858865/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!